Joseph C. Scodari Acquires 24,631 Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Stock

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Joseph C. Scodari purchased 24,631 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were purchased at an average cost of $1.01 per share, for a total transaction of $24,877.31. Following the completion of the purchase, the director now directly owns 27,708 shares in the company, valued at $27,985.08. The trade was a 800.49 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Acurx Pharmaceuticals Stock Performance

Shares of NASDAQ:ACXP opened at $0.81 on Friday. The stock has a 50-day simple moving average of $1.15 and a 200-day simple moving average of $1.76. The stock has a market capitalization of $13.65 million, a P/E ratio of -0.74 and a beta of -1.71. Acurx Pharmaceuticals, Inc. has a 1 year low of $0.68 and a 1 year high of $5.28.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. During the same period in the previous year, the business earned ($0.24) earnings per share. Analysts predict that Acurx Pharmaceuticals, Inc. will post -0.89 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Acurx Pharmaceuticals in a research report on Friday.

Institutional Investors Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Geode Capital Management LLC raised its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 12.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 146,500 shares of the company’s stock after acquiring an additional 16,485 shares during the quarter. Geode Capital Management LLC owned 0.90% of Acurx Pharmaceuticals worth $278,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.